A Phase II, Open-label, Tolerability and Efficacy Study of Civamide Nasal Solution, 0.01%, in Patients With Dry Eye Syndrome
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2017
Price : $35 *
At a glance
- Drugs Zucapsaicin (Primary)
- Indications Keratoconjunctivitis sicca
- Focus Therapeutic Use
- Sponsors Winston Laboratories
- 07 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jun 2015 Planned End Date changed from 1 Dec 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
- 03 Jun 2015 Planned primary completion date changed from 1 Oct 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov record.